JT001

JT001 (NLRP3-IN-19) is a potent, specific and orally active inhibitor of NLRP3. JT001 can inhibit NLRP3 inflammasome assembly, resulting in the inhibition of cytokine release and the prevention of pyroptosis. JT001 can be used for the research of nonalcoholic steatohepatitis and liver fibrosis[1].

Product Specifications

CAS Number

[2238819-65-1]

Product Name Alternative

NLRP3-IN-19

UNSPSC

12352005

Target

NOD-like Receptor (NLR)

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/jt001.html

Solubility

10 mM in DMSO

Smiles

O=C(NS(=O)(C1=C2OCCCN2N=C1)=O)NC3=C4CCCC4=CC5=C3CCC5

Molecular Formula

C19H22N4O4S

Molecular Weight

402.47

References & Citations

[1]Povero D, et, al. Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis. J Pharmacol Exp Ther. 2023 Aug;386 (2) :242-258.